PharmiWeb.com - Global Pharma News & Resources
15-Nov-2018

Anixa Biosciences To Present Cchek™ Breast Cancer Data at AACR Special Conference on Tumor Immunology and Immunotherapy

Anixa Biosciences To Present Cchek™ Breast Cancer Data at AACR Special Conference on Tumor Immunology and Immunotherapy

PR Newswire

SAN JOSE, Calif., Nov. 15, 2018

SAN JOSE, Calif., Nov. 15, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it will present data from its ongoing studies in breast cancer utilizing Cchek™, Anixa's artificial intelligence (AI) driven early cancer detection technology, at the AACR Special Conference on Tumor Immunology and Immunotherapy.  The conference is designed to integrate multidisciplinary facets of basic cancer immunology and immunotherapy to broaden the understanding of ways to harness the immune system to treat cancer.  The conference will be held November 27–30, 2018 in Miami Beach, Florida and will be attended by world-renowned oncologists and scientists who will offer new insights on systems biology, checkpoints, combination therapies, and molecular targets, all in the pursuit of finding new ways to manipulate the tumor immune microenvironment and creating better treatments.  To receive a copy of the presentation, please email your request to AACR-TII-2018@anixa.com starting November 30, 2018 and include your name, title, and contact information.

"We are pleased to make our presentation titled, Combining the immunophenotyping of MDSCs and lymphocytes with artificial intelligence (AI) to predict early stage breast cancer, at the AACR Tumor Immunology and Immunotherapy conference.  This data is focused on using our Cchek™ technology to detect breast cancer in its early stages.  The majority of screening technologies currently used for breast cancer detection, such as mammography, have the ability to detect later stage breast malignancies rather successfully but have shown difficulty with earlier stages," stated Dr. Amit Kumar, President and CEO of Anixa Biosciences.  "As we have previously announced, our initial commercial focus is on a prostate cancer test for which we will be meeting with the USFDA on December 17, 2018.  We recently presented our latest prostate cancer data at the 33rd Annual Meeting of The Society for Immunotherapy of Cancer (SITC), and we look forward to now present our latest breast cancer data at this AACR special conference," added Dr. Kumar.

American Association of Cancer Research (AACR)
The American Association of Cancer Research (AACR) (www.aacr.org) is a 501(c)(3) public charity headquartered in Philadelphia, PA.  The mission of the AACR is to prevent and cure cancer through research, education, communication and collaboration.  Through its programs and services, the AACR fosters cancer research and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer causes, prevention, diagnosis and treatment throughout the world.

About Anixa Biosciences, Inc.
Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer.  Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed.  It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy.  It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer.  Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization.  Additional information is available at www.anixa.com.

Forward-Looking Statements:  Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results.  We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements.  Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.  These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.  You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

View original content to download multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-to-present-cchek-breast-cancer-data-at-aacr-special-conference-on-tumor-immunology-and-immunotherapy-300750943.html

SOURCE Anixa Biosciences, Inc.

Editor Details

Last Updated: 15-Nov-2018